Interleukin (IL)-10 and glucocorticoids (GC) inhibit the ability of antigen-presenting dendritic cells (DC) to stimulate T lymphocytes. We show that induction of GILZ (GlucocorticoidInduced Leucine Zipper) is involved in this phenomenon. IL-10, dexamethasone (DEX) and transforming growth factor (TGF)ß stimulate GILZ production in human immature DC derived from monocytes and from CD34 + cells. GILZ is necessary and sufficient for DEX, IL-10 and TGFβ modulation of CD80, CD83, CD86, ILT3 and B7-H1 expression by DC and alteration of DC functions. GILZ stimulates the production of IL-10 by immature DC and it prevents the production of inflammatory chemokines by CD40L-activated DC. In contrast, GILZ does not prevent CD40L-mediated inhibition of phagocytosis, indicating that it affects some but not all aspects of DC maturation. GILZ prevents DC from activating antigen-specific T lymphocyte responses. Administration of GC to patients stimulates GILZ expression in their circulating antigen-presenting cells, and this contributes to the weak lymphocyte responses of GC-treated patients. Thus, regulation of GILZ expression is an important factor determining the decision of DC whether or not to stimulate T lymphocytes, and IL-10, GC and TGFß share this mechanism for influencing DC functions and the balance between immune response and tolerance.
INTRODUCTION
Dendritic cells (DC) play a critical role in the activation of T lymphocytes through their ability to capture, process and present antigens in association with MHC molecules. Interaction between the co-stimulatory molecules CD80 and CD86, expressed by DC, and CD28, expressed by T lymphocytes, is required for optimal T lymphocyte activation 1 . Immature DC express low levels of CD80 and CD86. They are activated by microbial-derived molecules through TLR, and this upregulates CD80/CD86 expression and ensures their maturation into fully efficient antigenpresenting cells. CD40 ligation also induces DC maturation and optimal T lymphocyte stimulation. Maturation of DC induced by TLR ligands and CD40L involves activation of the NF-κB and p38 MAP kinase pathways. DC may also generate immune tolerance by inducing T lymphocyte unresponsiveness or apoptosis, or by inducing T lymphocytes with regulatory functions 2 . The mechanisms by which antigen presentation by DC leads to opposite patterns of 4 Glucocorticoids (GC) are widely used to treat disorders involving uncontrolled immune activation, and especially autoimmune diseases, allergy and allograft rejection. Initial analyses focused on the effects of GC on T lymphocytes to explain their therapeutic properties, but recent reports show that the effects of GC are also due to silencing innate immune cells. In particular, GC alter the normal maturation of DC in response to TLR ligands and to CD40L. They downregulate the expression of CD80, CD86 and MHC molecules and the production of IL-12, whereas they stimulate the production of IL-10 13, 14 . IL-10 has similar effects on DC 15 ,
suggesting that the two agents share a common mechanism of action to interfere with DC maturation.
GILZ (Glucocorticoid-Induced Leucin Zipper) was identified in mice thymocytes treated with GC, protecting them from TCR/CD3-induced cell death 16 . Both GC and IL-10 stimulate the production of GILZ in mice and human monocytes/macrophages and GILZ is involved in GC and IL-10 anti-inflammatory effects 17 . GILZ blocks the NF-κB, MAPK and AP-1 signal transduction pathways in several types of cells [17] [18] [19] [20] . In view of the importance of these pathways in DC maturation, we addressed whether induction of GILZ in DC could explain why GC and IL-10 alter the maturation of DC and their ability to activate T lymphocytes.
MATERIALS AND METHODS

Antibodies and flow cytometry
The following mAbs FITC, PE or phycoerythrine-cyanin5 (PE-Cy5) were used: CD14-PE and CD80-PE from Becton Dickinson (Pont de Claix, France); CD3-PE, CD40-PE, CD34-PECy5, CD83-PE and ILT-3-PE-Cy5 from Beckman-Coulter (Villepinte, France); CD1a-PE-Cy5, CD86-FITC or -PE, HLA-DR-PE-Cy5 and CD90-FITC or -PE from Pharmingen (San Diego, CA, USA) and B7-H1-PE from Cliniscience (Montrouge, France). Negative controls were irrelevant isotype-matched mAbs. GILZ protein was labeled by incubation with a rabbit polyclonal anti-GILZ Ab 21 followed by a PE-conjugated anti-rabbit-F(ab') 2 (Jackson Immunoresearch, West Grove, PA containing 10% human AB serum (hABS), 20 ng/mL Interleukin 4 (IL-4, a kind gift from Dr K.Thielemans) and 100 ng/mL GM-CSF (Schering Plough, Levallois-Perret, France) for 9 days, the culture medium being changed on day 3 as described 22 , giving immature Mo-DC. To induce activation and maturation of DC, trimeric CD40 ligand (CD40L, 250 ng/mL, Immunex , Seattle, WA) was added on day 7 of culture. To obtain CD34-DC, leukapheresis samples from patients with solid tumors in remission were obtained after stem-cell mobilization with G-CSF/cyclophosphamide. CD34 + cells were purified using immunomagnetic beads as described 23 and frozen in FCS containing 10% dimethylsulfoxide until use. CD34 + cells were thawed and seeded in 12-well tissue-culture plates (Costar, Cambridge, MA) at 5x10 5 cells/mL in 2mL of RPMI 1640 medium containing 10% hABs, 1% L-glutamine, 1% antibiotics, Stem Cell Factor (300 ng/mL, a gift from Amgen, Thousands Oaks), Flt3-Ligand (50 ng/mL, a gift from Immunex, Seattle, WA), 100 ng/mL GM-CSF and TNFα (5 ng/mL, Valbiotech, France). On day 5, cells were seeded at 2.5 to 5x10 5 cells/mL and incubated for an additional seven days in the same culture medium supplemented with 50 ng/mL IL-4, the medium being changed at day 8. In 6 some experiments, 250 ng/mL of CD40L was added on day 10. DEX (Sigma, L'isle d'Abeau, France) was used at 10 
RT-PCR studies
Expression of the human GILZ gene was measured as mRNA by real time RT-PCR, and results were expressed as arbitrary units, as previously described 17 .
7 EF1L-thy1/GILZ-W+ lentiviral vector (Lv GILZ). pHIV-EF1L-thy1/GILZ-W+ is a HIV1-derived vector composed of a bicistronic cassette coexpressing both the human thy1 reporter gene and GILZ by the mean of an IRES sequence from the encephalomyocarditis virus under the control of the full length Elongation Factor 1 alpha promoter (EF1L). pHIV-EF1L-thy1/GILZ-W+ also contains the cPPT (central polypurine tract) 26 25 .
Aliquots of 2x10 7 293T cells were seeded in 162cm 2 tissue culture flasks and co-transfected using the calcium phosphate method with 9.9µg of pMD.G, 23µg of pCMVΔR8.91 and 29µg of the bicistronic pHIV-EF1L-thy1/GILZ-W+ or pHIV-EF1L-thy1/TK-W+. The next day, medium was replaced with medium without serum and lentiviral supernatants were collected 24 hrs later.
The supernatants were spun at 800g and passed through a 0.45µm-pore-size filter (Costar, Cambridge, MA, USA), and concentrated by ultrafiltration using Centricon Plus-80 filter devices according to the manufacturer's instructions (Centricon Plus-80, molecular weight cutoff 100kDa; Millipore, Bedford, MA). Concentrated supernatants were stored in aliquots at -80°C until further use. Viral titers were determined using 293T indicator cells as previously described 25 , and were 2x10 8 to 10 9 infectious particles/mL.
Transfer of GILZ gene
Mo-DC were transduced with pGILZ or pcDNA3 17 by nucleofection after 7 days of culture, as described by the kit manufacturer (Amaxa System, Köln, Germany). Nucleofection efficiency, assessed using a GFP-reporter vector, was tested by flow cytometry 24 hours later: 59 + 6 % (3 experiments) of the cells were GFP-positive. CD34-DC were infected with lentiviral vectors on 8 day 8 of culture. Briefly, 10 5 cells were suspended in 400µL of culture medium containing lentiviral supernatants at a multiplicity of infection of 100 and 8 µg/ml protamine sulfate and centrifuged at 20°C at 1000g for 3 hours (spinoculation) 25 . The cells were then further cultured as described above. Transduction efficiency was assessed on day 12 of culture by flow cytometry using anti-CD90 mAbs, and was 21.9 + 4.7% for Lv GILZ and 29.4 + 6.6% for Lv TK (mean + SEM of 5 separate experiments).
RNA interference experiments
The 21-nt-long interfering RNA duplexes with two 3'-end overhanging dT nucleotides on the antisense strand were synthesized. The sequences of the antisense strands of the siRNAs were for GILZ siRNA (siGILZ): 5'-AGU CCA GGA UUA UAG CCC CdTdT ; and for control siRNA (siC) with random nucleotides and no known specificity: 5'-ACG GGG GGC CCU UAA AAC AdTdT (MWG Biotec, Ebersberg, Germany or Dharmacon, Lafayette, CO).
Nucleofection of Mo-DC with siRNAs was conducted on day 6 of culture. Then, DEX, IL-10 or medium alone were added and the samples cultured for 24 hours. CD34-DC were transfected with siRNAs on day 8 using the JetSi endo transfection kit (Q-Biogene, Illkirch, France) as described by the manufacturer. Twenty-four hours later, the cells were washed and cultured as described above in the presence or absence of DEX or IL-10 until day 12. For APC, freshly isolated cells were transfected using the JetSi endo transfection kit.
Lymphocyte responses
Mo-DC or APC from BCG-vaccinated individuals were loaded with PPD (1 μg/mL, Statens Serum Institute, Copenhagen, Denmark) for 4 hours, washed and co-cultured (0.5x10 5 DC) with 1x10 5 freshly purified autologous CD4 + T-cells in round-bottomed 96-well culture plates in RPMI + 10% hABs. CD4 + T-cells were purified by negative selection using immunomagnetic beads (Dynal). In some experiments DC were transfected with siRNAs 24 hours before the end 9 of the Mo-DC culture. The response of CD4 + T lymphocytes was analyzed at the single cell level on day 7 of the co-culture using the dye Pkh26 (Sigma-Aldrich, Saint Quentin Fallavier, France), as previously described 27 . For MLR, allogeneic T-cells were purified from PBMC using immunomagnetic beads as described 25 and frozen until use. Thirty gray-irradiated CD34-DC were mixed in triplicate round-bottomed wells with 10 5 freshly thawed allogeneic T-cells/well and co-cultured in 200µL of RPMI + 10% hABs at 37°C for 5 days. Each CD34-DC preparation was tested against T lymphocytes from 3 unrelated donors. Cell proliferation was assayed by
Results are expressed as mean counts per minute (cpm).
ELISA assays
Production of cytokines and chemokines was assessed using ELISA kits from Diaclone (Besançon, France) for IFNγ and IL-10 and from R&D Systems for CCL3, CCL5 and CXCL8.
Endocytosis assay
The uptake ability of GILZ-expressing DC was measured using FITC-conjugated dextran particles (FITC-Dx, Sigma) diluted in PBS at 10mg/mL and used at a final concentration of 1mg/mL in culture medium. GILZ-expressing DC were seeded in culture medium at 1x10 6 cells/mL, kept at 37°C for 30min and then incubated with FITC-Dx at 37°C for 1 hour. Negative control of uptake was cells tested at 4°C. Then, cells were washed four times in cold PBS and analyzed immediately by FACS. When the endocytosis of FITC-Dx was studied on lentivirallyinfected CD34-DC, cells were stained with CD90-PE mAbs prior to the uptake assay and analysis was performed on gated CD90 + CD34-DC, considered as transduced cells.
RESULTS
Expression of GILZ by DC
We monitored gilz gene expression by real time RT-PCR during the differentiation of monocyte-derived DC (Mo-DC). Freshly isolated monocytes expressed the gilz gene. This expression disappeared after 5 days of culture in the presence of GM-CSF + IL-4, and remained undetectable both in the presence and in the absence of CD40L-induced DC maturation.
Addition of DEX led to an upregulation of gilz gene expression. This expression was maintained even in the presence of CD40L (Fig 1a) . When DEX was added on day 5 and removed on day 7, gilz expression then declined to disappear by day 9, regardless of the addition of CD40L (Fig   1b) . Therefore, gilz gene induction is reversible and its persistence depends on the continuous presence of DEX. IL-10 and TGFß also stimulated gilz gene expression by DC, although to a lesser extent than DEX (Fig 1a) . gilz gene expression was also studied during the differentiation of DC from CD34 + cells (CD34-DC). Freshly isolated CD34 + cells expressed the gilz gene strongly and this expression was progressively lost during their dendritic differentiation.
Addition of DEX or IL-10 increased gilz gene expression and the increase persisted after CD40L addition (Fig 1c) . Therefore, DEX and IL-10 stimulate gilz gene expression in immature DC, and this expression persists upon CD40L triggering. When DEX or IL-10 were added on day 7 to Mo-DC or on day 10 to CD34-DC, no induction of gilz gene expression was observed, regardless of the addition of CD40L (data not shown), indicating that sensitivity of DC to GC and IL-10 was restricted to a specific step of their differentiation. Expression of GILZ by Mo-DC was also studied by flow cytometry using an anti-GILZ polyclonal Ab. No GILZ was detected in immature Mo-DC cultured without DEX. Addition of DEX, IL-10 or TGFß stimulated GILZ production (Fig 1d, upper panels and data not shown). Western blot studies gave similar findings (data not shown). 
Modulation of DC phenotype by GILZ
We determined whether GILZ is involved in the phenotypic changes of Mo-DC induced by DEX or IL-10. Inhibition of GILZ production was obtained by transfecting Mo-DC with GILZ small interfering (si)RNA. The GILZ siRNA prevented the DEX-or IL-10 induced production of GILZ mRNA, as assessed by real-time RT-PCR, and of GILZ protein, as assessed by flow cytometry and by western blotting. A control siRNA had no effect (Fig 1d, lower panels and data not shown).
DEX and IL-10 changed the phenotype of Mo-DC. When added on day 5 of culture to DC transduced with control siRNA, they inhibited the expression of CD80, CD83 and CD86, and they stimulated the expression of B7-H1. DEX and IL-10 inconsistently inhibited the expression of MHC class II molecules and stimulated that of ILT3 (Fig 2a and data not shown) . In these experiments, expression of CD83 by control cells was higher than expected for DC cultured in the absence of differentiating agents, reflecting a partial activation of DC by nucleofection.
Transduction of DC with GILZ siRNA prevented DEX-and IL-10-induced changes of phenotype: GILZ siRNA partially restored CD80 and CD83 expression and completely restored CD86 expression; it abolished induction of B7-H1 and ILT3 (Fig 2a) . In experiments in which DEX or IL-10 inhibited MHC class II expression, this effect was reversed by GILZ siRNA (data not shown). Thus, GILZ is involved in the DEX-and IL-10-induced changes of Mo-DC phenotype. Next, a GILZ-encoding vector (pGILZ) was introduced into Mo-DC and cell phenotype was determined 24 hours later. We verified by flow cytometry and western blotting that nucleofection of Mo-DC with pGILZ resulted in production of the GILZ protein (data not shown). The effect of GILZ on CD86 expression was inconsistent. In contrast, GILZ-producing DC expressed lower levels of CD80 and CD83 and higher levels of B7-H1 and ILT3 than did DC transfected with a control vector (Fig 2b) . Therefore, GILZ is sufficient to cause changes of DC phenotype. 
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The effect of GILZ on the production of IL-10 and chemokines by DC Treatment of immature Mo-DC with DEX stimulates their production of IL-10 14 . We investigated whether GILZ was involved in this effect. DEX stimulated IL-10 production in Mo-DC transfected with control siRNA. In contrast, transfection with GILZ siRNA partially prevented DEX-induced upregulation of IL-10 production. We next tested the effect of gilz gene transfer into Mo-DC. Mo-DC nucleofected with pGILZ produced ~6 fold more IL-10 than control cells nucleofected with pcDNA3 (Table I) . Therefore, induction of GILZ is at least partially responsible for the DEX-mediated stimulation of IL-10 production by DC. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 15 Activation of Mo-DC with CD40L stimulated the production of the chemokines CCL3, CCL5 and CXCL8, but this was partially prevented by treatment with DEX or IL-10. Transfection of GILZ siRNA inhibited the effect of each DEX and IL-10 on chemokine production, whereas transfection with control siRNA had no effect (Fig 3) . 
GILZ effect on DC maturation
The impact of GILZ expression on DC maturation was evaluated. Mo-DC were nucleofected with either pcDNA3 or pGILZ, stimulated or not with CD40L, and tested for dextran particles phagocytosis. As expected, the expression of CD80 and CD83 was lower in cells nucleofected with pGILZ than in controls (Fig 4a) . In immature Mo-DC, phagocytosis of dextran was similar between GILZ-expressing and control cells. CD40L-induced activation of Mo-DC abolished phagocytosis to a similar extent in GILZ-expressing and control cells (Fig   4b) . In these experiments, phagocytosis of dextran by immature Mo-DC nucleofected with either pcDNA3 or pGILZ was lower than in cells not nucleofected, whereas expression of CD80 and CD83 was stronger (data not shown). This indicates that nucleofection induced a partial maturation of Mo-DC. To avoid this, we generated GILZ-producing CD34-DC using lentiviral-mediated transfer of the gilz gene. A thymidine kinase-encoding lentivirus was used as control. Both lentiviruses also encoded for the CD90 reporter gene, and phenotypic changes were analyzed in CD90 + CD34-DC. In the absence of CD40L activation, CD34-DC expressed no CD83 and only low levels of CD80. GILZ expression partially inhibited the upregulation of CD80 and CD83 induced by CD40L (Fig 4c) . In immature CD34-DC, phagocytosis was slightly higher in GILZ-expressing cells than in controls (Fig 4d) .
Activation of CD34-DC with CD40L abolished phagocytosis in both GILZ-expressing and control cells. These findings confirm those obtained with Mo-DC, showing that GILZ has dissociated effects on the maturation of DC, preventing some but not all parameters of this process. 
GILZ-expressing DC and T lymphocyte activation
To test the ability of GILZ-expressing DC to activate T lymphocytes, Mo-DC were transfected with control or GILZ siRNA, cultured with or without DEX or IL-10 and loaded with 18 PPD. DC were then mixed with autologous Pkh26-labeled CD4 + T lymphocytes, and proliferation of lymphocytes was followed. Treatment of DC with DEX or IL-10 decreased their ability to stimulate CD4 + T lymphocytes (data not shown). The effect of DEX and IL-10 was preserved when DC were transfected with control siRNA. In contrast, GILZ siRNA abolished the effect of DEX or IL-10 on DC, restoring a strong proliferative response to PPD (Fig 5a) . The effect of GILZ expression by DC on IFNγ production by CD4 + T lymphocytes was also tested.
PPD-loaded Mo-DC stimulated IFNγ production by autologous CD4 + T lymphocytes. Treating DC with either DEX or IL-10 inhibited the production of IFNγ by CD4 + T lymphocytes. This inhibition was abolished when DC were transfected with GILZ siRNA, whereas control siRNA had no effect (Fig 5b) .
The role of GILZ on CD34-DC-induced allogeneic response was also tested. Treatment of CD34-DC with DEX or IL-10 decreased their ability to stimulate the proliferation of allogeneic T lymphocytes. Transfection of CD34-DC with control siRNA had no effect, regardless of the addition of DEX or IL-10. Transfection with GILZ siRNA slightly enhanced proliferation in the absence of DEX or IL-10. It totally reversed the inhibitory effect of DEX and IL-10 (Fig 5c) .
We tested whether GILZ expression in DC was sufficient to decrease CD4 + T lymphocyte stimulation. Mo-DC transfected with pGILZ or a control vector were loaded with PPD, washed and cocultured with autologous CD4 + T lymphocytes. The proliferation of CD4 + T lymphocytes was lower when GILZ-expressing DC were used as antigen-presenting cells (APC) (Fig 5d) .
Expression of GILZ in DC also decreased the production of IFNγ by CD4 + T lymphocytes (20.1 + 11.3 % as compared to the production with control DC, p<0.05). We tested whether TGFβ has similar effects on DC than DEX. Treatment of DC with TGFβ inhibited their expression of CD80, CD83 and CD86, and it upregulated the expression of B7-H1. These effects were reversed when DC were nucleofected with GILZ siRNA (Fig 6A) . When
TGFβ-treated DC were used to present PPD, they stimulated CD4 + T lymphocytes to a lesser extent than control DC. This defect was reversed when DC where treated with GILZ siRNA ( Fig   6B) . Therefore, TGFβ-treated DC display phenotypic and functional alterations close to those of DEX-treated DC, and these changes also involve GILZ production by DC. (Table I) . Therefore, induction of GILZ is responsible for the DEXmediated stimulation of IL-10 production by DC.
In vivo induction of GILZ by GC treatment
gilz gene expression was quantified by real-time PCR in circulating APC from patients treated with GC for various inflammatory disorders. Analyses were performed before and 48 hours after initiation of treatment. GC stimulated gilz gene expression by circulating APC (535 ± 43 AU of GILZ mRNA (mean ± SEM), vs 151 ± 35 AU before GC administration, p<0.05).
The ability of circulating APC from GC-treated patients to stimulate an antigen-specific CD4+ T lymphocyte response was tested. APC from GC-treated patients stimulated CD4+ T lymphocytes poorly, as assessed by proliferative and IFNγ production assays (data not shown).
Findings were similar when APC were transfected with a control siRNA. In contrast, APC from GC-treated patients generated strong proliferation and IFNγ production when they were transfected with GILZ siRNA (Fig 7) . Therefore, in GC-treated patients, GILZ expression by 23 circulating APC is increased, and this explains their poor effectiveness at triggering an antigenspecific CD4 + T lymphocyte response. and MHC molecules, a decreased production of chemokines, which contribute to T lymphocyte activation 28, 29 , and an increased expression of IL-10, B7-H1 and ILT3. This redundancy of mechanisms may ensure a strong and consistent inhibition of T lymphocyte activation by GILZexpressing DC regardless of their origin and of their environmental conditions.
TGFß also upregulated GILZ production by DC. TGFß acts on T lymphocyte to prevent immune activation. However, TGFß also affects DC functions directly 8, 9 , and our findings show that GILZ induction is involved in this effect. GILZ production may thus be a common mechanism of immune control shared by several immunosuppressive cytokines. Interestingly, both IL-10 and TGFß are produced by T lymphocytes with regulatory functions 12 , suggesting that these cells may control immune activation at least partly by inducing GILZ expression in DC. Because GILZ-expressing DC themselves produce IL-10, a self-amplifying loop may be induced locally to inhibit inflammation and immune activation.
GILZ inhibits cell activation via various molecular targets. It prevents NF-κB activation, at least partly by binding directly to its p65 subunit [17] [18] [19] . It also interferes with the MAPK pathway and the induction of AP-1 19, 20 . These signal transduction pathways are central to the maturation of DC, so a simple explanation of the effect of GILZ on DC function would be that it prevents DC maturation. The observation that GILZ inhibits several CD40L-induced modifications of DC, such as chemokine production and upregulation of co-stimulatory and MHC molecules, is consistent with this possibility. We also observed that GILZ prevents LPS-induced maturation of DC (data not shown). As immature DC are poor activators of T lymphocytes and may even promote tolerance, this would account for the inhibitory effect of GILZ on T lymphocyte responses. However, GILZ does not prevent all consequences of DC maturation, as it does not affect CD40L-induced inhibition of phagocytosis. Moreover, GILZ has specific effects, such as upregulation of IL-10 and B7-H1 expression. Expression of B7-H1 increases with DC maturation 5, 7, 30 , and therefore induction of IL-10 and B7-H1 by GILZ is not consistent with GILZ only preventing DC maturation. These observations rather suggest that GILZ drives DC to an alternative pathway of differentiation, leading to DC with many features of tolerogenic DC.
The action of GILZ on DC maturation, regardless of its mechanism, presumably explains why IL-10 and TGFß affect the function of immature DC but are not effective on fully mature DC For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 10, 11, 15 . The inability of DEX and IL-10 to induce GILZ when added to on fully differentiated DC may also explain this phenomenon.
Since their introduction as therapy, GC have become a cornerstone in most immunosuppressive treatments. Although their mechanisms of action remain incompletely understood, antigenpresenting cells are critical targets to their therapeutic effect. GC stimulate synthesis of IκBα and thus prevent NF-κB activation 31, 32 , suggesting a possible mechanism of GC action in DC.
However, the intracellular effects of GC appear much more complex than initially thought, involving several molecular targets. We show here that GC administration to humans stimulates GILZ expression by circulating APC and that GILZ induction accounts for the poor efficacy of APC from GC-treated patients to stimulate T lymphocytes. Indeed, neutralization of GILZ by RNA interference restores fully potent antigen presentation by APC from GC-treated patients.
By inducing GILZ in DC, GC may reproduce for therapeutic purposes a natural mechanism of immune regulation induced by immunosuppressive cytokines including IL-10 and TGFß.
Evidence from genetically-modified mice demonstrates that IL-10 and TGFß are central to immune tolerance [33] [34] [35] [36] [37] . In human and in mice, GILZ is constitutively produced by antigen- 
